Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha joining 21 (TRAJ21) is a gene segment located within the TCR alpha locus in humans and mice. It encodes a joining (J) region element used during the somatic VJ (variable-joining) recombination process in developing T cells, which permits immense diversity within the antigen-recognition sites of T cell receptors (TCRs). The TRAJ21 segment does not encode a functional protein on its own but is incorporated into the mature TCR alpha chain when recombined with a variable (Vα) gene segment and the constant (Cα) region in developing T cells. Its role is conserved across species and is essential for generation of TCR diversity, but it is not a direct therapeutic, drug, or diagnostic target[1][4][6]. In summary: TRAJ21 is a J-gene segment of the TCR alpha locus, essential for adaptive immunity, but is not a distinct receptor, nor a direct therapeutic target or biomarker. Any reference to it as a druggable target or receptor is incorrect, though it is functionally indispensable for T cell antigen recognition[1][4][6].
Null. Not applicable, as there are no drugs that interact directly with this gene segment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining 21 (TRAJ21).